Compare Stocks → AI Bubble Now at Critical Mass (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNXNASDAQ:ATOSNASDAQ:EPIX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsATOSAtossa Therapeutics$1.80-1.6%$1.09$0.59▼$1.94$225.54M1.16956,747 shs1.25 million shsEPIXESSA Pharma$8.50-0.7%$9.01$2.56▼$11.67$376.04M1.64158,789 shs62,403 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%-82.64%ATOSAtossa Therapeutics+1.67%+12.27%+86.72%+87.48%+167.19%EPIXESSA Pharma-3.28%-6.96%+6.47%+20.73%+187.25%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNXAthenexN/AN/AN/AN/AN/AN/AN/AN/AATOSAtossa Therapeutics1.1261 of 5 stars3.51.00.00.03.80.00.0EPIXESSA Pharma3.0596 of 5 stars3.54.00.00.03.03.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenexN/AN/AN/AN/AATOSAtossa Therapeutics3.00Buy$4.50150.00% UpsideEPIXESSA Pharma3.00Buy$16.5094.12% UpsideCurrent Analyst RatingsLatest ATNX, ATOS, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.001/12/2024ATOSAtossa TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00ATOSAtossa TherapeuticsN/AN/AN/AN/A$0.93 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AATOSAtossa Therapeutics-$26.96M-$0.24N/AN/AN/AN/A-24.80%-23.82%N/AEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)Latest ATNX, ATOS, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AATOSAtossa TherapeuticsN/A-$0.06-$0.06N/AN/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72ATOSAtossa TherapeuticsN/A28.3528.35EPIXESSA PharmaN/A40.7440.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%ATOSAtossa Therapeutics12.74%EPIXESSA Pharma75.12%Insider OwnershipCompanyInsider OwnershipATNXAthenex9.20%ATOSAtossa Therapeutics7.80%EPIXESSA Pharma14.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableATOSAtossa Therapeutics11125.30 million115.53 millionOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableATNX, ATOS, and EPIX HeadlinesSourceHeadlineESSA Pharma Inc. (NASDAQ:EPIX) Short Interest Updatemarketbeat.com - March 16 at 6:46 PMEPIX Jul 2024 7.500 callfinance.yahoo.com - March 10 at 1:42 PMEPIX Jul 2024 12.500 putfinance.yahoo.com - March 10 at 1:42 PMESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSprnewswire.com - March 7 at 8:13 PMESSA Pharma: Q1 Earnings Insightsbenzinga.com - February 13 at 2:14 PMESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023finance.yahoo.com - February 13 at 9:13 AMESSA Pharma Inc Executive Peter Virsik Sells 72,782 Sharesfinance.yahoo.com - February 8 at 12:15 AMESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 9:15 AMESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gainsfinance.yahoo.com - January 22 at 9:58 AMEssa Pharma Inc (EPIX) receives an Outperform rating from Oppenheimerknoxdaily.com - January 1 at 1:31 PMEPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…finance.yahoo.com - December 20 at 5:36 PMESSA Pharma Stock (NASDAQ:EPIX) Earnings Dates and Earning Callsbenzinga.com - December 14 at 6:00 PMESSA Pharma Stock (NASDAQ:EPIX) Dividends: History, Yield and Datesbenzinga.com - December 12 at 11:07 PMRecap: ESSA Pharma Q4 Earningsbenzinga.com - December 12 at 1:07 PMEPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023investorplace.com - December 12 at 12:08 PMESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023finance.yahoo.com - December 12 at 8:07 AMBullish ESSA Pharma Insiders Loaded Up On US$1.19m Of Stockfinance.yahoo.com - December 11 at 9:40 AMESSA Pharma director Franklin Berger buys common shares worth ~$133.3Kmsn.com - November 24 at 11:58 AMESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conferencefinance.yahoo.com - November 21 at 10:18 AMESSA Pharma to Present at the Jefferies London Healthcare Conferencefinance.yahoo.com - November 8 at 9:32 AMWe Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business Growthfinance.yahoo.com - October 31 at 2:38 PMEPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat…finance.yahoo.com - October 30 at 3:37 PMESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congressfinance.yahoo.com - October 21 at 1:27 PMEPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23…finance.yahoo.com - August 14 at 3:20 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAthenexNASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Atossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.